CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
FACULTY DISCLOSURE DECLARATION
According to the disclosure policy of the University of Cincinnati, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosure will be made at the time of activity.
In accordance with the ACCME Standards for Commercial Support, the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (eg, paid speaker, employee, paid consultant on a board, and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation. The following disclosures were made:
Millie D. Long, MD, MPH, discloses the following relationships with commercial interests: AbbVie Inc., Pfizer Inc., Takeda Pharmaceuticals USA, Inc., and TARGET PharmaSolutions (Consultant); Takeda Pharmaceuticals USA, Inc. (Research Support); and AbbVie Inc. and UCB (Speaker).
Meenakshi Bewtra, MD, MPH, PhD, discloses the following relationships with commercial interests: Janssen Pharmaceuticals, Inc. (Consultant); GlaxoSmithKline and Takeda Pharmaceuticals USA, Inc. (Research Support); and AbbVie Inc. (Speaker).
Derek R. Patel, MD, discloses the following relationships with commercial interests: AbbVie Inc. (Consultant) and AbbVie Inc. (Speaker).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Crohn’s & Colitis Foundation
Sudha Sarode, MSPH, has no relevant relationships to disclose.
RMEI Medical Education, LLC
Sherri Kramer, MD, has no relevant relationships to disclose.
Tania Dickson has no relevant relationships to disclose.
Jessica Hatch has no relevant relationships to disclose.
University of Cincinnati
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, CME Director, has no relevant relationships to disclose.
Rick E. Ricer, MD, Professor Emeritus, has no relevant relationships to disclose.
Deborah Cole, BS, has no relevant relationships to disclose.
OFF-LABEL DISCLOSURE STATEMENT
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
LEARNER ASSURANCE STATEMENT
The University of Cincinnati is committed to resolving all conflict of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
The opinions expressed during the enduring material activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Estimated time to complete: 1.0 hour
There is no fee for this educational activity.
This activity is supported by independent educational grants from AbbVie Inc., Celgene Corporation, Salix Pharmaceuticals, and Takeda Pharmaceuticals USA, Inc.
HOW TO RECEIVE CREDIT
By completing the curriculum challenge (at the beginning and again at the end of the activity), the pre test, reviewing the course content, and successfully completing the post test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1.0 AMA PRA Category 1 Credit™. A statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post test and evaluation will receive CME credit. You must score 75% or higher on the post test to receive credit for this activity. All other participants who successfully complete the post test and evaluation will receive a certificate of participation.
Please contact the University of Cincinnati Continuing Medical Education Department at email@example.com
or by calling 513-558-7277.
For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center